AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 33966329
Drug: Prediction equations
RxNorm normalized name: reductic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prediction equations for estimating body weight in females aged 65-79 years using height, MUAC, WC, CC, and TST.
Trial: 33966329
Drug: Prediction equations
RxNorm normalized name: reductic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prediction equations for estimating body weight in females aged ≥ 80 years using height, MUAC, WC, CC, and TST.
Trial: 33966329
Drug: Prediction equations
RxNorm normalized name: reductic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prediction equations for estimating body weight in males aged 65-79 years using height, MUAC, WC, CC, and TST.
Trial: 33966329
Drug: Prediction equations
RxNorm normalized name: reductic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prediction equations for estimating body weight in males aged ≥ 80 years using height, MUAC, WC, CC, and TST.
Trial: 34959148
Drug: 400 µg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 µg misoprostol
Trial: 32046747
Drug: Pycnogenol supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pycnogenol supplementation of 150 mg for 10 days
Trial: 33021477
Drug: Etanercept 50
RxNorm normalized name: etanercept 50 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etanercept 50 mg subcutaneous injection
Trial: 35796769
Drug: Treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as usual informed by autofluorescence imaging
Trial: 35796769
Drug: Treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as usual alone (control)
Trial: 34374108
Drug: Duloxetine 60mg
RxNorm normalized name: DULOXETINE 60MG CAP,SPRINKLE,EC
DrugBank: Duloxetine (DB00476)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Duloxetine 60mg daily for 6 weeks (5 weeks full dose and 1 week taper)
Trial: 32165813
Drug: Graded Activity
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Graded Activity with Daily-Monitored-Walking (GAMW)
Trial: 34444779
Drug: Cranberry juice
RxNorm normalized name: cranberry juice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cranberry juice (500 mL/d; 27% cranberry juice)
Trial: 34424347
Drug: Vaginal hysterectomy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaginal hysterectomy with apical suspension (VH)
Trial: 38934231
Drug: Control/delayed treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control/delayed treatment group
Trial: 34358471
Drug: Liraglutide 3.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liraglutide 3.0 mg daily
Trial: 32077553
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g of IV acetaminophen + 1 mg of IV hydromorphone
Trial: 32077553
Drug: Placebo +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo + 1 mg of IV hydromorphone
Trial: 34318607
Drug: Sovesudil (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sovesudil (both doses)
Trial: 34632925
Drug: Dolcanatide 27
RxNorm normalized name: Dolcanatide
DrugBank: Dolcanatide (DB13112)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dolcanatide 27 mg daily for 7 days
Trial: 32056528
Drug: 70% sterile
RxNorm normalized name: ALCOHOL,ISOPROPYL 70% STERILE LIQ,TOP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 70% sterile honey‐based ophthalmic formulation
Trial: 32056528
Drug: 0.3% ophthalmic
RxNorm normalized name: Zymar 0.3% Ophthalmic Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3% ophthalmic ciprofloxacin
Trial: 33080740
Drug: IV lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV lidocaine at 1.5 mg/kg
Trial: 34407441
Drug: Nigella sativa
RxNorm normalized name: NIGELLA SATIVA SEED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nigella sativa oil (NSO) 500 mg twice daily for 10 days
Trial: 34800794
Drug: dHACM Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dHACM Injection
Trial: 33798297
Drug: Combination group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination group (TEAS + epidural)
Trial: 33825333
Drug: Foam and
RxNorm normalized name: Proshield Foam and Spray Cleanser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Foam and cream for rosacea patients (verum)
Trial: 32078025
Drug: Treatment of
RxNorm normalized name: DRUGS FOR TREATMENT OF LEPRA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment of body-focused repetitive behaviors
Trial: 32178526
Drug: DPI (rivaroxaban
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DPI (rivaroxaban 2.5 mg twice daily plus aspirin 100 mg once daily)
Trial: 36327436
Drug: HTD1801 500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HTD1801 500 mg BID
Trial: 36327436
Drug: HTD1801 1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HTD1801 1000 mg BID
Trial: 32151562
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg lactoferrin
Trial: 32151562
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg lactoferrin
Trial: 34752990
Drug: Humane treatment
RxNorm normalized name: Insulin Human
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Humane treatment behaviors
Trial: 33607121
Drug: Preparation time
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preparation time ≥10 minutes
Trial: 33092501
Drug: Granulocyte colony-stimulating
RxNorm normalized name: Granulocyte colony-stimulating factor lenograstim
DrugBank: Lenograstim (DB13144)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Granulocyte colony-stimulating factor (G-CSF) administered via continuous intravenous infusion at a dosage of 90 μg/kg
Trial: 33096120
Drug: Grape juice
RxNorm normalized name: grape juice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Grape juice group (GJG) consuming 400 ml of grape juice per day for 1 month
Trial: 33096120
Drug: Placebo and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo and exercise group (PLEG) with concurrent physical training
Trial: 33096120
Drug: Grape juice
RxNorm normalized name: grape juice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Grape juice and exercise group (GJEG) with concurrent physical training
Trial: 33426861
Drug: No add-on
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No add-on treatment (Group B).
Trial: 34158057
Drug: No insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: No insulin treatment
Trial: 34582657
Drug: Zinc Supplement
RxNorm normalized name: Zinc supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zinc Supplement (45 mg of elemental zinc for 12 weeks)
Trial: 33883008
Drug: HTL0018318 (15–35
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HTL0018318 (15–35 mg/day)
Trial: 34174217
Drug: High-dose pitavastatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose pitavastatin 4mg
Trial: 34174217
Drug: Low-dose pitavastatin
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose pitavastatin 1mg
Trial: 33439266
Drug: Prostate radiation
RxNorm normalized name: Sus scrofa prostate preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prostate radiation therapy (PRT) added to androgen deprivation therapy (ADT)
Trial: 38462613
Drug: Intravitreal dexamethasone
RxNorm normalized name: Dexamethasone Intravitreal Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal dexamethasone implant (IDI)
Trial: 32173165
Drug: Cartoon-assisted preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cartoon-assisted preparation package for endoscopy
Trial: 35357323
Drug: Personalized treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Personalized treatment that tailored complexity parameters based on participants' self-reported capabilities and goals
Trial: 35357323
Drug: Control treatment
RxNorm normalized name: SALICYLIC ACID 190 mg in 1 mL TOPICAL LIQUID [Derma E Acne Blemish Control Treatment Serum]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control treatment with complexity parameters set generically based on national guidelines
Trial: 33141936
Drug: Low-trigger transfusion
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-trigger transfusion (haemoglobin below 8.0 g/dL)
Trial: 33141936
Drug: High-trigger transfusion
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-trigger transfusion (haemoglobin below 9.7 g/dL)
Trial: 33744844
Drug: Health IT
RxNorm normalized name: DIPHENHYDRAMINE HYDROCHLORIDE 2 mg in 100 mL TOPICAL GEL [A Health Itch Relief Gel]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Health IT intervention using the Patient Buddy app focusing on ascites, medications, and hepatic encephalopathy over 30 days.
Trial: 34792188
Drug: Sublingual immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual immunotherapy (SLIT) with Dermatophagoides farinae drops
Trial: 34792188
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment (topical glucocorticoids, skin moisturizers, oral antihistamines, allergen avoidance)
Trial: 34710894
Drug: Individual Metacognitive
RxNorm normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Individual Metacognitive Interpersonal Therapy (MIT) combined with Group Mentalization-Based Treatment (MBT)
Trial: 36084129
Drug: Cultural adaptation
RxNorm normalized name: casein, emmental cultured
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cultural adaptation promotion resilience program (CAPRP), performed for 60 minutes, twice a week for four weeks
Trial: 33125944
Drug: IMRT with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IMRT with cetuximab and avelumab (10 mg/kg day 7 and every 2 weeks) followed by avelumab every two weeks for 12 months (arm B and C)
Trial: 33125944
Drug: Intensity Modulated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensity Modulated Radiation Therapy (IMRT) with cisplatin (100 mg/m2 Q3W) (arm A)
Trial: 33125944
Drug: Intensity Modulated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensity Modulated Radiation Therapy (IMRT) with weekly cetuximab (arm D)
Trial: 33326576
Drug: HPV-vaccine arm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HPV-vaccine arm
Trial: 36042627
Drug: Whey protein
RxNorm normalized name: Whey protein
DrugBank: Whey (DB18685)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whey protein (10 g/d) with resistance training (3 times a week)
Trial: 36042627
Drug: Placebo (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (10 g/d) with resistance training (3 times a week)
Trial: 35658926
Drug: Combined oral
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined oral contraceptives (Control)
Trial: 34913959
Drug: Apatinib 500
RxNorm normalized name: Apatinib
DrugBank: Rivoceranib (DB14765)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apatinib 500 mg/d
Trial: 33289973
Drug: Hydroxychloroquine (800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroxychloroquine (800 mg once, followed by 400 mg daily for 6 days)
Trial: 33289973
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care (no specific therapy)
Trial: 35982468
Drug: Optional combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optional combined interventions (multi-media messages, nicotine replacement therapy sampling, financial incentive for active referral, phone counselling, and family/peer support group chat)
Trial: 32350792
Drug: Non-vitamin K
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-vitamin K oral anticoagulants (NOACs) such as apixaban and edoxaban
Trial: 32901243
Drug: Desensitizing-containing hydrogen
RxNorm normalized name: Hydrogen
DrugBank: Hydrogen (DB15127)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desensitizing-containing hydrogen peroxide gel (5% potassium nitrate)
Trial: 32901243
Drug: Desensitizing-free hydrogen
RxNorm normalized name: Hydrogen
DrugBank: Hydrogen (DB15127)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desensitizing-free hydrogen peroxide gel (35%)
Trial: 33842864
Drug: Rapid-test-guided treatment
RxNorm normalized name: Abreva Rapid Pain Relief
DrugBank: Glycerin (DB09462)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rapid-test-guided treatment for ASB
Trial: 32445190
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg Δ9-THC
Trial: 32445190
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg Δ9-THC
Trial: 32004693
Drug: Vi-DT Typhoid
RxNorm normalized name: Typhoid Vi polysaccharide vaccine
DrugBank: Typhoid Vi polysaccharide vaccine (DB10803)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vi-DT Typhoid Conjugate Vaccine
Trial: 35676445
Drug: Multimodal deep
RxNorm normalized name: Deep Sea
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multimodal deep learning architecture for therapy personalization
Trial: 33784987
Drug: Lung-protective ventilation
RxNorm normalized name: beef lung preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lung-protective ventilation (LPV) with a tidal volume (Vt) of 7 ml kg−1 ideal body weight (IBW), 10 cmH2O positive end-expiratory pressure (PEEP) combined with regular recruitment maneuvers (RMs)
Trial: 33784987
Drug: Conventional ventilation
RxNorm normalized name: VENTILATOR FILTER,THERMOFLO #6000S
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional ventilation (CV) with a Vt of 10 ml kg−1 IBW, 0 cmH2O in PEEP and no RMs
Trial: 33128399
Drug: Combination with
RxNorm normalized name: Iron in combination with folic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination with Autogenous Bone Grafts (AG)
Trial: 33128399
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of mPPT and AG
Trial: 33128399
Drug: rhFGF-2 therapy
RxNorm normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: rhFGF-2 therapy
Trial: 32363638
Drug: Gabapentin (GBP)
RxNorm normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gabapentin (GBP) 100 mg/day orally for 6 weeks
Trial: 32363638
Drug: Hydroxyzine (HYDZ)
RxNorm normalized name: Hydroxizine
DrugBank: Hydroxyzine (DB00557)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydroxyzine (HYDZ) 25 mg/day orally for 6 weeks
Trial: 33541495
Drug: rhTPO 15,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rhTPO 15,000 U, once daily for 7 days
Trial: 32337693
Drug: Sheng Xue
RxNorm normalized name: Ji Xue Cao Whole
DrugBank: Centella asiatica (DB14256)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sheng Xue Ning (SXN) tablets
Trial: 32337693
Drug: Ferrous succinate
RxNorm normalized name: Ferrous succinate
DrugBank: Ferrous fumarate (DB14491)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ferrous succinate (FS) tablets
Trial: 33899450
Drug: ALMAG +
RxNorm normalized name: almagate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ALMAG + magnetic therapy device
Trial: 32484754
Drug: Standard-of-care (SOC)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-of-care (SOC) treatments (arm 1)
Trial: 34479861
Drug: Control (twice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (twice with SP)
Trial: 32579813
Drug: Hydroxyurea with
RxNorm normalized name: Hydroxyurea
DrugBank: Hydroxyurea (DB01005)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroxyurea with dose escalation (approximately 30 mg per kilogram per day)
Trial: 32579813
Drug: Hydroxyurea at
RxNorm normalized name: Hydroxyurea
DrugBank: Hydroxyurea (DB01005)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroxyurea at a fixed dose (approximately 20 mg per kilogram of body weight per day)
Trial: 32579813
Drug: Dose escalation
RxNorm normalized name: PALFORZIA Initial Dose Escalation KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose escalation group
Trial: 615918278
Drug: Intravitreal aflibercept
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal aflibercept injection (IAI) 2.0 mg every 8 weeks after 3 initial monthly doses (2q8)
Trial: 35114057
Drug: acute treatment-related
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: acute treatment-related toxicity
Trial: 32744358
Drug: metformin +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: metformin + PEX168 100 μg
Trial: 32744358
Drug: metformin +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: metformin + PEX168 200 μg
Trial: 35272403
Drug: High-frequency acupuncture
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: High-frequency acupuncture (5 times weekly for weeks 1-4, 3 times weekly for weeks 5-8)
Trial: 35272403
Drug: Low-frequency acupuncture
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-frequency acupuncture (3 times weekly for weeks 1-4, 2 times weekly for weeks 5-8)
Trial: 33860924
Drug: Vericiguat plus
RxNorm normalized name: Vericiguat
DrugBank: Vericiguat (DB15456)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Vericiguat plus guideline-directed medical therapy (GDMT)
Trial: 33860924
Drug: Guideline-directed medical
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guideline-directed medical therapy (GDMT) plus placebo
Trial: 33091174
Drug: High fermentable
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High fermentable fiber intake (13 g)
Trial: 33091174
Drug: Low fermentable
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low fermentable fiber intake (≤ 2 g)
Trial: 36691173
Drug: Two doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two doses of 11.4 mg betamethasone
Trial: 34627611
Drug: DMUC4064A (5.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DMUC4064A (5.2 mg/kg RP2D)
Trial: 34627611
Drug: DMUC4064A (≥3.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DMUC4064A (≥3.2 mg/kg)
Trial: 32174632
Drug: Bach flower
RxNorm normalized name: flowers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bach flower therapy (BFT)
Trial: 35508656
Drug: Intermittent dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent dosing of PI3Kδi
Trial: 34558835
Drug: Ipragliflozin (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ipragliflozin (50 mg/day for 72 weeks)
Trial: 34558835
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no SGLT2is, pioglitazone, GLP-1 analogs, or insulin)
Trial: 36241463
Drug: Pitavastatin 2
RxNorm normalized name: PITAVASTATIN 2MG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pitavastatin 2 mg plus ezetimibe 10 mg
Trial: 36241463
Drug: Pitavastatin 4
RxNorm normalized name: PITAVASTATIN 4MG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pitavastatin 4 mg plus ezetimibe 10 mg
Trial: 35392963
Drug: Probenecid (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probenecid (1 g orally twice per day for 180 days)
Trial: 34115990
Drug: Dose Optimization
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose Optimization for Stone Evaluation intervention (customized CME modules, personalized consultation, and protocol recommendations for RDCT)
Trial: 36217872
Drug: Inclisiran sodium
RxNorm normalized name: inclisiran sodium
DrugBank: Inclisiran (DB14901)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Inclisiran sodium 300 mg/284 mg (free acid) administered at days 1, 90, 270 and 450
Trial: 32703194
Drug: Oral morphine
RxNorm normalized name: morphine Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral morphine drops (5 mg, four daily doses for 1 week)
Trial: 35384021
Drug: Low-dose rituximab
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose rituximab (500 mg, 2 weeks apart)
Trial: 35384021
Drug: Rheumatoid arthritis
RxNorm normalized name: Rheumatoid arthritis nuclear antibody
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rheumatoid arthritis protocol (1000 mg given as two doses, 2 weeks apart)
Trial: 35384021
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups received short-term oral corticosteroids
Trial: 32268815
Drug: Pomalidomide, bortezomib,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pomalidomide, bortezomib, and low-dose dexamethasone (PVd)
Trial: 32268815
Drug: Bortezomib and
RxNorm normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bortezomib and low-dose dexamethasone (Vd)
Trial: 34459271
Drug: Education (brief
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Education (brief psychoeducation and treatment resources)
Trial: 34459271
Drug: Education+Motivation (Education
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Education+Motivation (Education plus treatment seeking-focused motivational content)
Trial: 32078787
Drug: AkP05 nutraceutical
RxNorm normalized name: ZINC OXIDE 154 mg in 1 mL TOPICAL LOTION [Ultraceuticals Ultra UV Protective Daily Moisturising]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AkP05 nutraceutical combination